Literature DB >> 31514980

An in vitro study on interaction of anisodine and monocrotaline with organic cation transporters of the SLC22 and SLC47 families.

Jia-Yin Chen1, Jürgen Brockmöller2, Mladen V Tzvetkov2, Li-Jun Wang1, Xi-Jing Chen3.   

Abstract

Current study systematically investigated the interaction of two alkaloids, anisodine and monocrotaline, with organic cation transporter OCT1, 2, 3, MATE1 and MATE2-K by using in vitro stably transfected HEK293 cells. Both anisodine and monocrotaline inhibited the OCTs and MATE transporters. The lowest IC50 was 12.9 µmol·L-1 of anisodine on OCT1 and the highest was 1.8 mmol·L-1 of monocrotaline on OCT2. Anisodine was a substrate of OCT2 (Km = 13.3 ± 2.6 µmol·L-1 and Vmax = 286.8 ± 53.6 pmol/mg protein/min). Monocrotaline was determined to be a substrate of both OCT1 (Km = 109.1 ± 17.8 µmol·L-1, Vmax = 576.5 ± 87.5 pmol/mg protein/min) and OCT2 (Km = 64.7 ± 14.8 µmol·L-1, Vmax = 180.7 ± 22.0 pmol/mg protein/min), other than OCT3 and MATE transporters. The results indicated that OCT2 may be important for renal elimination of anisodine and OCT1 was responsible for monocrotaline uptake into liver. However neither MATE1 nor MATE2-K could facilitate transcellular transport of anisodine and monocrotaline. Accumulation of these drugs in the organs with high OCT1 expression (liver) and OCT2 expression (kidney) may be expected.
Copyright © 2019 China Pharmaceutical University. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Anisodine; MATE; Monocrotaline; OCT; Organic cation transporter

Mesh:

Substances:

Year:  2019        PMID: 31514980     DOI: 10.1016/S1875-5364(19)30070-6

Source DB:  PubMed          Journal:  Chin J Nat Med        ISSN: 1875-5364


  3 in total

Review 1.  Transport of Drugs and Endogenous Compounds Mediated by Human OCT1: Studies in Single- and Double-Transfected Cell Models.

Authors:  Bastian Haberkorn; Martin F Fromm; Jörg König
Journal:  Front Pharmacol       Date:  2021-04-22       Impact factor: 5.810

2.  VARIDT 2.0: structural variability of drug transporter.

Authors:  Tingting Fu; Fengcheng Li; Yang Zhang; Jiayi Yin; Wenqi Qiu; Xuedong Li; Xingang Liu; Wenwen Xin; Chengzhao Wang; Lushan Yu; Jianqing Gao; Qingchuan Zheng; Su Zeng; Feng Zhu
Journal:  Nucleic Acids Res       Date:  2022-01-07       Impact factor: 16.971

3.  Structure-dependent genotoxic potencies of selected pyrrolizidine alkaloids in metabolically competent HepG2 cells.

Authors:  Lukas Rutz; Lan Gao; Jan-Heiner Küpper; Dieter Schrenk
Journal:  Arch Toxicol       Date:  2020-09-10       Impact factor: 5.153

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.